FOLH1 and cancer: The Ongoing PATRON trial (NCT04557501) and PSMA-SRT trial (NCT03582774) are two randomized Phase III studies that will evaluate cancer outcomes of treatment intensification with PSMA PET/CT compared to conventional imaging on a 5-year perspective and will certainly help to clarify how to manage these oligometastatic patients.